focus -WSS

focus

author：Wikipedia 2025-09-30 18:59:22 - browse：11159

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. Her OB-GYN had put her on Effexor for her depression 20 years ago, and it worked well enough — she could sleep for the first time in her life, and she no longer cried at every little thing. But it never worked for her dark thoughts.

But then she retired, and then she had time, and then she saw an email — “I guess once your name gets on a list, it’s there,” she said — for an experimental depression drug called zuranolone.

Unlike today’s crowded market of SSRIs, prescribed once and taken for months, years, or even indefinitely, zuranolone, developed by Sage Therapeutics, promises something different.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Readout Newsletter: BridgeBio, Akero, and human embryo models

WSS

For AI in health care standards, federal regulators join with industry group

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Francis Collins on trust in science and how Covid communications failed

$1 billion proposal to grow Boston, Massachusetts biotech

Think you might have Covid

My yearlong odyssey to get my son’s ADHD medication covered

focus

focus

hotspot

Hollywood unions extend contract negotiations for actors

Ancient Greek ideas underpin modern concepts of pregnancy

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

IVF doctors demand details after CooperSurgical lawsuit

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Jerome Adams on the need for new antivirals for Covid

How digital therapeutics firms are pivoting after Pear's bankruptcy

hotspot

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

For AI in health care standards, federal regulators join with industry group

Families look for replacement for GSK asthma drug Flovent

How digital therapeutics firms are pivoting after Pear's bankruptcy

My yearlong odyssey to get my son’s ADHD medication covered

Change Healthcare: What is it, why does its cyberattack matter?

knowledge

leisure time

entertainment

Wikipedia